



November 07, 2017

National Stock Exchange of India Limited,
Compliance Department,
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai - 400051,
Maharashtra, India

BSE Limited,
Compliance Department,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400001,
Maharashtra, India

Sub : Disclosure of the Outcome of the Board Meeting under Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Ref : HealthCare Global Enterprises Limited ("the Company") (NSE Scrip Code: HCG/ BSE Scrip Code: 539787)

Dear Sir/Madam,

We wish to inform you that the Board of Directors of the Company, at their meeting held on this day, the 7th November 2017, *inter alia*, has considered and approved the Unaudited Financial Results, both Standalone and Consolidated (Limited Review), for the quarter and half year ended September 30, 2017.

The Board also deliberated on the proposal for issuance of Equity Shares of the Company on a Preferential basis; and in this regard has advised the Management to seek additional clarifications.

Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith the Unaudited Financial Results (Standalone and Consolidated) for the quarter and half year ended September 30, 2017.

The Meeting of the Board concluded at 3.45 P.M.

Request you to take this on record.

For HealthCare Global Enterprises Limited

Sunu Manuel
Company Secretary & Compliance Officer



Encl: as above

HealthCare Global Enterprises Ltd.

HCG Tower, # 8, P. Kalinga Rao Road, Sampangi Ram Nagar, Bangalore - 560 027

91 80 3366 9999 | info@hcgoncology.com | www.hcgoncology.com | CIN: L15200KA1998PLC023489

B S R & Co. LLP

Chartered Accountants

Maruthi Info-Tech Centre
11-12/1 Inner Ring Road
Koramangala
Bangalore 560 071 India

Telephone +91 80 7134 7000
Fax +91 80 7134 7999

Limited Review Report on quarterly and year to date unaudited standalone financial results of HealthCare Global Enterprises Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To the Board of Directors of HealthCare Global Enterprises Limited

We have reviewed the accompanying statement of unaudited standalone financial results ("Statement") of HealthCare Global Enterprises Limited ('the Company') for the quarter and six months ended 30 September 2017 attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Regulations, 2015').

This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors of the Company. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company's personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

The unaudited standalone financial results for the corresponding quarter and six months ended 30 September 2016 and the audited standalone financial results for the year ended 31 March 2017 included in the Statement, were reviewed and audited, respectively by the predecessor auditor, whose limited review report dated 10 November 2016 and audit report dated 24 May 2017 expressed an unmodified opinion on those unaudited/ audited standalone financial results.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with applicable accounting standards i.e. Ind AS prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of SEBI Regulations, 2015 and SEBI Circular dated 5 July 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

for **B S R & Co. LLP**

Chartered Accountants

Firm's registration number: 101248W/W-100022



Amit Somani

Partner

Membership number: 060154

Place: Bengaluru

Date: 7 November 2017

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED 30 SEPTEMBER 2017

(Rs. in Lakhs except share data)

Sl. No.	Particulars	3 Months ended 30-09-2017	Preceding 3 months ended 30-06-2017	Corresponding 3 months ended 30- 09-2016 in the previous year	Year to date figures for the current period ended 30-09-2017	Year to date figures for the previous period ended 30-09-2016	Previous year ended 31-03-2017
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Income						
	(a) Revenue from Operations	14,646	13,377	13,627	28,023	26,994	53,878
	(b) Other income	163	212	199	375	395	722
	Total Income	14,809	13,589	13,826	28,398	27,389	54,600
2	Expenses						
	(a) Purchases of stock in trade	3,920	4,216	3,875	8,136	7,696	15,265
	(b) Changes in inventory of stock in trade	(27)	(384)	(162)	(411)	(321)	(317)
	(c) Employee benefits expense	2,961	2,631	2,472	5,592	4,771	9,656
	(d) Finance costs	587	465	333	1,052	670	1,456
	(e) Depreciation and amortisation expense	1,018	987	1,064	2,005	2,101	4,256
	(f) Medical consultancy charges	2,680	2,527	2,668	5,207	5,245	10,543
	(g) Other expenses	2,895	2,562	2,633	5,457	5,434	10,229
	Total expenses	14,034	13,004	12,883	27,038	25,596	51,088
3	Profit before exceptional items and tax (1-2)	775	585	943	1,360	1,793	3,512
4	Exceptional items	-	-	-	-	-	-
5	Profit before tax (3-4)	775	585	943	1,360	1,793	3,512
6	Tax expense						
	- Current tax	180	136	189	316	371	754
	- Deferred tax	90	68	142	158	241	406
	Total tax	270	204	331	474	612	1,160
7	Profit for the period / year (5-6)	505	381	612	886	1,181	2,352
8	Other comprehensive income						
	(i) Items that will not be reclassified to the statement of profit and loss						
	- Remeasurements (losses) on defined benefit plans	-	-	-	-	-	(18)
	- Income tax on (i) above	-	-	-	-	-	6
	(ii) Items that will be reclassified to Statement of profit and loss						
	- Effective portion of loss on designated portion of hedging instrument in a cashflow hedge	(29)	-	-	(29)	-	-
	- Income tax on (ii) above	10	-	-	10	-	-
	Other comprehensive income for the period / year	(19)	-	-	(19)	-	(12)
9	Total comprehensive income for the period / year, net of tax (7+8)	486	381	612	867	1,181	2,340
10	Paid-up equity share capital (Face value of Rs. 10 each)	8,571	8,571	8,508	8,571	8,508	8,571
11	Reserves excluding revaluation reserves, i.e., 'Other equity' as per balance sheet of previous accounting year	-	-	-	-	-	46,537
12	Earnings per equity share (face value of Rs. 10 each)						
	(a) Basic	0.58	0.45	0.72	1.03	1.39	2.86
	(b) Diluted	0.58	0.45	0.72	1.03	1.38	2.85
	See accompanying notes to the Standalone Financial Results						



BSA

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED 30 SEPTEMBER 2017

BALANCE SHEET

Rs in Lakhs

Particulars	As at	As at
	30-9-2017	31-3-2017
	Unaudited	Audited
A ASSETS		
I Non-current assets		
(a) Property, plant and equipment	42,016	41,167
(b) Capital work in progress	3,169	3,342
(c) Other intangible assets	546	542
(e) Financial assets		
(i) Investments	17,907	13,398
(ii) Loans	2,657	1,138
(iii) Other financial assets	7,438	2,411
(f) Deferred tax assets (net)	870	1,001
(g) Income tax assets (net)	2,476	2,533
(h) Other non-current assets	2,634	1,868
	79,713	67,400
II Current assets		
(a) Inventories	1,841	1,431
(b) Financial assets		
(i) Investments	-	749
(ii) Trade receivables	11,939	10,024
(iii) Cash and cash equivalents	555	7,394
(iv) Loans	451	184
(v) Other financial assets	2,748	1,989
(c) Other current assets	1,219	921
	18,753	22,692
Total assets	98,466	90,092
B EQUITY AND LIABILITIES		
I Equity		
(a) Equity share capital	8,571	8,571
(b) Other equity	47,620	46,637
Total equity	56,191	55,208
II Liabilities		
1 Non-current liabilities		
(a) Financial liabilities		
(i) Borrowings	17,230	9,880
(ii) Other financial liabilities	1,032	154
(b) Provisions	275	237
(c) Other non-current liabilities	121	116
	18,658	10,387
2 Current liabilities		
(a) Financial liabilities		
(i) Borrowings	1,615	4,126
(ii) Trade payables	11,477	10,273
(iii) Other financial liabilities	8,229	8,022
(b) Other current liabilities	1,772	1,622
(c) Provisions	524	454
	23,617	24,497
Total equity and liabilities	98,466	90,092



STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED 30 SEPTEMBER 2017

Notes:

1 The statement of unaudited standalone financial results ('the Statement') of HealthCare Global Enterprises Limited ('the Company') for the quarter and six months ended 30 September 2017, has been reviewed by the Audit and Risk Management Committee and approved by the Board of Directors at their meeting held on 07 November 2017. The Statement has been subjected to limited review by the statutory auditor of the Company. The report of the auditor is unqualified. The Statement has been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under section 133 of the Companies Act, 2013 read with the relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI circular dated 05 July 2016.

2 The statement of category wise utilisation of net proceeds from Initial Public Offer is:

Category wise utilisation of net proceeds from Initial Public Offer	(Rs. In Lakhs)	
	Amount proposed to be utilised	Actual utilisation as on 30-9-2017
Purchase of medical equipment	4,220	-
Investment in IT software, services and hardware	3,019	255
Pre-payment of debt	14,704	14,700
General corporate purposes	1,977	950
Total	23,920	15,905

Details of unutilised funds as on 30 September 2017	(Rs. In Lakhs)
Investment in fixed deposits	4,490
Amount parked in cash credit account	3,525
Total	8,015

3 The Company has a single operating segment of 'setting up and managing hospitals and medical diagnostic services'.

4 Prior period / year figures have been reclassified wherever required to confirm to the classification of the current period.



For and on behalf of the Board of Directors

(Signature)
D. B. S. Ajaikumar
Chairman and CEO

Bengaluru, 07 November 2017

B S R & Co. LLP

Chartered Accountants

Maruthi Info-Tech Centre
11-12/1 Inner Ring Road
Koramangala
Bangalore 560 071 India

Telephone +91 80 7134 7000
Fax +91 80 7134 7999

Limited Review Report on quarterly and year to date unaudited consolidated financial results of HealthCare Global Enterprises Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To the Board of Directors of HealthCare Global Enterprises Limited

We have reviewed the accompanying statement of unaudited consolidated financial results ("Statement") of HealthCare Global Enterprises Limited ('the Company'), its subsidiaries and an associate (collectively referred to as 'the Group'), listed in the Annexure, for the quarter and six months ended 30 September 2017 attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Regulations, 2015').

This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors of the Company. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

The unaudited consolidated financial results for the corresponding quarter and six months ended 30 September 2016 and the audited consolidated financial results for the year ended 31 March 2017 included in the Statement, were reviewed and audited, respectively by the predecessor auditor, whose limited review report dated 10 November 2016 and audit report dated 24 May 2017 expressed an unmodified opinion on those unaudited/ audited consolidated financial results.

We did not review the financial information of two subsidiaries, a step-down subsidiary and an associate included in the Statement. These subsidiaries including a step-down subsidiary account for Rs. 11 lakhs and Rs. 73 lakhs of net loss, Rs. 3 lakhs and Rs. 12 lakhs of total revenues (including other income) for the quarter and six months ended 30 September 2017 respectively and Rs. 3,074 lakhs of total assets as at 30 September 2017. The Statement also includes the Group's share of net loss of Rs. 39 lakhs and an exceptional item of Rs 640 lakhs being gain on account of change in control for the quarter and six months ended 30 September 2017 in respect of an associate. The unaudited financial information of these subsidiaries, a step-down subsidiary and an associate have been reviewed by the other auditors whose reports have been furnished to us by the Company's Management. Our report on the Statement, in so far as it relates to these subsidiaries and an associate, is based solely on the aforesaid review reports of the other auditors.



HealthCare Global Enterprises Limited
Limited Review report (continued)

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with applicable accounting standards i.e. Ind AS prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of SEBI Regulations, 2015 and SEBI Circular dated 5 July 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

for B S R & Co. LLP

Chartered Accountants

Firm's registration number: 101248W/W-100022



Amit Somani

Partner

Membership number: 060154

Place: Bengaluru

Date: 7 November 2017

HealthCare Global Enterprises Limited

Annexure to the Review Report

S. No.	Entity	Subsidiary/ Step- down subsidiary/ Associate	Country of incorporation
1	BACC Health Care Private Limited	Subsidiary	India
2	DKR Healthcare Private Limited	Step-down subsidiary	India
3	HCG Medi-Surge Hospitals Private Limited	Subsidiary	India
4	HCG Oncology LLP	Subsidiary	India
5	HealthCare Diwan Chand Imaging LLP	Subsidiary	India
6	HCG NCHRI Oncology LLP	Subsidiary	India
7	HCG EKO Oncology LLP	Subsidiary	India
8	HCG Pinnacle Oncology Private Limited	Subsidiary	India
9	APEX HCG Oncology Hospitals LLP	Subsidiary	India
10	HCG Regency Oncology Healthcare Private Limited	Subsidiary	India
11	HCG Manavata Oncology LLP	Subsidiary	India
12	Niruja Product Development and Healthcare Research Private Limited (formerly known as MIMS HCG Oncology Private Limited)	Subsidiary	India
13	HCG (Mauritius) Pvt. Ltd.	Step-down subsidiary	Mauritius
14	HealthCare Global Senthil Multi Specialty Hospitals Private Limited	Subsidiary	India
15	Malnad Hospital and Institute of Oncology Private Limited	Subsidiary	India
16	Healthcare Global (Africa) Pvt. Ltd. Group (subsidiary till 30 June 2017)	Associate	Mauritius



STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED 30 SEPTEMBER 2017

(Rs. in Lakhs except share data)

Sl. No.	Particulars	3 Months ended 30-09-2017	Preceding 3 months ended 30-06-2017	Corresponding 3 months ended 30-09-2016 in the previous year	Year to date figures for the current period ended 30-09-2017	Year to date figures for the previous period ended 30-09-2016	Previous year ended 31-03-2017
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Income						
	(a) Revenue from operations	21,107	19,110	17,398	40,217	34,153	70,011
	(b) Other income	190	242	236	432	439	967
	Total income	21,297	19,352	17,634	40,649	34,592	70,978
2	Expenses						
	(a) Purchases of stock in trade	4,678	5,424	4,438	10,102	8,727	17,592
	(b) Changes in inventory of stock in trade	139	(876)	(278)	(737)	(448)	(501)
	(c) Employee benefits expense	4,093	3,516	3,098	7,609	5,977	12,192
	(d) Finance costs	1,045	696	576	1,741	1,098	2,300
	(e) Depreciation and amortisation expense	1,670	1,524	1,439	3,194	2,695	5,684
	(f) Medical consultancy charges	4,460	4,064	4,111	8,524	7,793	15,593
	(g) Other expenses	4,630	4,032	3,489	8,662	7,201	14,635
	Total expenses	20,715	18,380	16,873	39,095	33,043	67,495
3	Profit before exceptional items, share of loss of equity accounted investee and tax (1-2)	582	972	761	1,554	1,549	3,483
4	Exceptional items (refer note 4)	640	-	-	640	-	-
5	Profit before share of loss of equity accounted investee and income tax (3+4)	1,222	972	761	2,194	1,549	3,483
6	Share of loss of equity accounted investee	(39)	-	-	(39)	-	-
7	Profit before tax (5+6)	1,183	972	761	2,155	1,549	3,483
8	Tax expense						
	- Current tax	272	244	275	516	557	270
	- Deferred tax	(71)	120	(4)	49	1	909
	Total tax	201	364	271	565	558	1,179
9	Profit for the period / year (7-8)	982	608	490	1,590	991	2,304
10	Other comprehensive income						
	(i) Items that will not be reclassified to the statement of profit and loss						
	- Remeasurements (losses) on defined benefit plans	-	-	-	-	-	(10)
	- Income tax on (i) above	-	-	-	-	-	4
	(ii) Items that will be reclassified to Statement of profit and loss						
	- Effective portion of loss on designated portion of hedging instrument in a cashflow hedge	(29)	-	-	(29)	-	-
	- Income tax on (ii) above	10	-	-	10	-	-
	Other comprehensive income for the period / year	(19)	-	-	(19)	-	(6)
11	Total comprehensive income for the period / year (9+10)	963	608	490	1,571	991	2,298
	Profit for the period / year attributable to:						
	Equityholders of the Company	1,001	473	494	1,474	992	2,217
	Non-controlling interests	(19)	135	(4)	116	(1)	87
	Other comprehensive income for the period / year attributable to						
	Equityholders of the Company	(19)	-	-	(19)	-	(7)
	Non-controlling interests	-	-	-	-	-	1
	Total comprehensive income for the period / year attributable to						
	Equityholders of the Company	982	473	494	1,455	992	2,210
	Non-controlling interests	(19)	135	(4)	116	(1)	88
12	Paid-up equity share capital (Face value of Rs. 10 each)	8,571	8,571	8,508	8,571	8,508	8,571
13	Reserves excluding revaluation reserves, i.e., 'Other equity' as per balance sheet of previous accounting year	-	-	-	-	-	34,695
14	Earnings per share (face value of Rs. 10 each)						
	(a) Basic	1.17	0.55	0.58	1.72	1.17	2.69
	(b) Diluted	1.17	0.55	0.58	1.72	1.16	2.69
	See accompanying notes to the Consolidated Financial Results						




STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED 30 SEPTEMBER 2017

CONSOLIDATED BALANCE SHEET

(Rs in Lakhs)

Particulars	As at	As at
	30-9-2017	31-3-2017
	Unaudited	Audited
A ASSETS		
I Non-current assets		
(a) Property, plant and equipment	76,245	61,701
(b) Capital work in progress	9,335	14,823
(c) Goodwill	6,089	6,089
(d) Other intangible assets	920	681
(e) Investment in equity accounted investee	2,251	-
(f) Financial assets		
(i) Investments	491	395
(ii) Loans	323	293
(iii) Other financial assets	11,512	4,786
(g) Deferred tax assets (net)	1,854	1,671
(h) Income tax assets (net)	2,676	2,613
(i) Other non-current assets	5,896	5,175
	117,592	98,227
II Current assets		
(a) Inventories	2,656	1,877
(b) Financial assets		
(i) Investments	-	749
(ii) Trade receivables	12,290	10,322
(iii) Cash and cash equivalents	2,161	8,522
(iv) Loans	483	202
(v) Other financial assets	1,402	1,385
(c) Other current assets	1,578	1,360
	20,570	24,417
Total assets	138,162	122,644
B EQUITY AND LIABILITIES		
I Equity		
(a) Equity share capital	8,571	8,571
(b) Other equity	34,423	34,695
Equity attributable to equity holders of the Company	42,994	43,266
Non- controlling interest	7,384	5,746
Total equity	50,378	49,012
II Liabilities		
1 Non-current liabilities		
(a) Financials Liabilities		
(i) Borrowings	39,464	28,338
(ii) Other financial liabilities	9,319	8,012
(b) Provisions	411	305
(c) Deferred tax liabilities (net)	363	117
(d) Other non-current liabilities	320	307
	49,877	37,079
2 Current liabilities		
(a) Financials liabilities		
(i) Borrowings	1,679	4,162
(ii) Trade payables	13,858	12,736
(iii) Other financial liabilities	19,215	16,734
(b) Other current liabilities	2,399	2,287
(c) Provisions	528	494
(d) Income tax liabilities (net)	228	140
	37,907	36,553
Total equity and liabilities	138,162	122,644




HealthCare Global Enterprises Limited

CIN : U15200KA1998PLC023489

Regd. Office: HCG Tower, No. 8, P Kalinga Rao Road, Sampangi Rama Nagar, Bengaluru 560 027, Karnataka, India

Corp. Office: Tower Block, Unity Building Complex, No. 3, Mission Road, Bengaluru 560 027, Karnataka, India

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED 30 SEPTEMBER 2017

Notes:

1 The statement of unaudited consolidated financial results ('the Statement') of HealthCare Global Enterprises Limited ('the Company'), its subsidiaries and an associate (collectively referred to as 'the Group') for the quarter and six months ended 30 September 2017, has been reviewed by the Audit and Risk Management Committee and approved by the Board of Directors at their meeting held on 07 November 2017. The Statement has been subjected to limited review by the statutory auditor of the Company. The report of the auditor is unqualified. The Statement has been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under section 133 of the Companies Act, 2013 read with the relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI circular dated 05 July 2016.

2 During the quarter ended 30 September 2017, the Company acquired 93.66% stake in Cancer Care Kenya Limited through its associate Healthcare Global (Africa) Private Limited .

3 The statement of category wise utilisation of net proceeds from Initial Public Offer is:

Category wise utilisation of net proceeds from Initial Public Offer	(Rs. In Lakhs)	
	Amount proposed to be utilised	Actual utilisation as on 30-9-2017
Purchase of medical equipment	4,220	-
Investment in IT software, services and hardware	3,019	255
Pre-payment of debt	14,704	14,700
General corporate purposes	1,977	950
Total	23,920	15,905

Details of unutilised funds as on 30 September 2017	(Rs. In Lakhs)
Investment in fixed deposits	4,490
Amount parked in cash credit account	3,525
Total	8,015

4 During the quarter ended 30 September 2017, investment in HealthCare Global (Africa) Private Limited, is accounted under equity method as per Ind AS 28 'Investment in Associates and Joint Ventures' on account of change in control and the resultant gain of Rs. 640 lakhs is shown under exceptional items.

5 The Group has a single operating segment of 'setting up and managing hospitals and medical diagnostic services.

6 Prior period / year figures have been reclassified wherever required to confirm to the classification of the current period.

For and on behalf of the Board of Directors

B. S. Ajai Kumar
Dr. B. S. Ajai Kumar
 Chairman and CEO



Bengaluru, 07 November 2017